The lymphoma and myeloma expert indicated that one of the key ways to address these disparities in lymphoma and myeloma is to improve minority and rural accrual in clinical trials.
This study found that regional- and distant-stage prostate cancer incidence continues to increase in US men aged ≥50 years.
The American Society for Radiation Oncology recently conducted an online survey of 222 US based, practicing radiation oncologists, finding that 100% continued to provide radiation therapy services during the COVID-19 pandemic.
A recent study found that phase I queue designs were associated with a reduction in the expected study duration without changing risk limits or maximum tolerated dose determination when compared to the original parent design.
Stephen Schuster, MD, explained how Penn Medicine is utilizing at-home treatments, which will continue after the pandemic, to maximize safety and reduce hospital traffic during the COVID-19 pandemic.
This phase II trial suggested that combination immune checkpoint inhibition with durvalumab plus tremelimumab may be associated with prolonged overall survival in patients with advanced refractory colorectal cancer.
Researchers highlighted the current challenges, risks, and future implications for global oncology trial management as a result of the COVID-19 pandemic.
The FDA approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.
The VEGF TKI induced durable responses and favorable tolerability in patients with relapsed/refractory RCC.
The associate professor of Medicine spoke about the use of of telemedicine in genetic counseling before the COVID-19 pandemic, how it is used today, and how telemedicine may be utilized in this space moving forward.
This study found that a biweekly unidirectional text-messaging intervention did not reduce aromatase inhibitor adherence failure in women with breast cancer.
Ambereen K. Mehta, MD, MPH, and Thomas J. Smith, MD, highlighted the necessity for palliative care services for patients with cancer to continue amidst the COVID-19 pandemic.
A recent examination of older adults with cancer found accelerated losses in differing sarcopenia measures existed before and after a cancer diagnosis.
Atezolizumab was approved as a first-line treatment for adults with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, as determined by an FDA approved test, with no EGFR or ALK genomic tumor aberrations.
A study found that dexrazoxane, a cardioprotective drug, preserved cardiac function without compromising overall survival and event-free survival for pediatric patients with acute myeloid leukemia.